Kaken Pharmaceutical Co Ltd (4521) - Financial and Strategic SWOT Analysis Review

December 2021 | 40 pages | ID: K6EA328D709EN
GlobalData

Abstracts

Kaken Pharmaceutical Co Ltd (4521) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kaken Pharmaceutical Co Ltd (Kaken) is a specialty pharmaceutical company that conducts research and develops drugs, agrochemicals and medical equipment. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergies, fungal infections and pain relief. Kaken also offers fungicides, rice herbicide, anti-coccidial for chickens and polypeptide antibiotics. The company conducts research in inflammation and immunology, neurological pain relief and fungal infection areas. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Tokyo, Japan.

Kaken Pharmaceutical Co Ltd Key Recent Developments

Jan 13,2021: Numab Therapeutics and Kaken Pharmaceutical form Co-Development alliance for a next-generation atopic dermatitis treatment option
Mar 10,2020: HitGen and Kaken enter into license agreement

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Kaken Pharmaceutical Co Ltd - Key Facts
Kaken Pharmaceutical Co Ltd - Key Employees
Kaken Pharmaceutical Co Ltd - Key Employee Biographies
Kaken Pharmaceutical Co Ltd - Major Products and Services
Kaken Pharmaceutical Co Ltd - History
Kaken Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Kaken Pharmaceutical Co Ltd - Business Description
Business Segment: Agrochemicals
Overview
Performance
Business Segment: Others
Performance
Business Segment: Pharmaceuticals and Medical Devices
Overview
Performance
Business Segment: Real Estate
Overview
Performance
R&D Overview
Kaken Pharmaceutical Co Ltd - Corporate Strategy
Kaken Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Kaken Pharmaceutical Co Ltd - Strengths
Kaken Pharmaceutical Co Ltd - Weaknesses
Kaken Pharmaceutical Co Ltd - Opportunities
Kaken Pharmaceutical Co Ltd - Threats
Kaken Pharmaceutical Co Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kaken Pharmaceutical Co Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jan 13, 2021: Numab Therapeutics and Kaken Pharmaceutical form Co-Development alliance for a next-generation atopic dermatitis treatment option
Mar 10, 2020: HitGen and Kaken enter into license agreement

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Kaken Pharmaceutical Co Ltd, Key Facts
Kaken Pharmaceutical Co Ltd, Key Employees
Kaken Pharmaceutical Co Ltd, Key Employee Biographies
Kaken Pharmaceutical Co Ltd, Major Products and Services
Kaken Pharmaceutical Co Ltd, History
Kaken Pharmaceutical Co Ltd, Subsidiaries
Kaken Pharmaceutical Co Ltd, Key Competitors
Kaken Pharmaceutical Co Ltd, Ratios based on current share price
Kaken Pharmaceutical Co Ltd, Annual Ratios
Kaken Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
Kaken Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
Kaken Pharmaceutical Co Ltd, Interim Ratios
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kaken Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Kaken Pharmaceutical Co Ltd, Performance Chart (2017 - 2021)
Kaken Pharmaceutical Co Ltd, Ratio Charts
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kaken Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021